The issue of cost-effectiveness remains critical in oncology to ensure the sustainability of treatments.[21] The cost-effectiveness of CDK4/6 inhibitors for the treatment of HR+/HER2− advanced breast cancer has been analyzed in some of the literature,[22–27] but the results of the literature may be different from the results of the scores in this evaluation. Here, CDK4 is linked to breast carcinoma.